QuidelOrtho (NASDAQ:QDEL) Azioni

QuidelOrtho

QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.

Quidel

QuidelOrtho Corp

In the latest quarter, 4 analysts provided ratings for QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $49.75, a high estimate of $61.00, and a low estimate of $43.00. A 1.15% drop is evident in the current average compared to the previous average price target of $50.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1739476846_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive QuidelOrtho. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$61.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$43.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to QuidelOrtho. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of QuidelOrtho compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for QuidelOrtho's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into QuidelOrtho's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/QDEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on QuidelOrtho analyst ratings.</a>
<h2>Get to Know QuidelOrtho Better</h2>
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.
<h3>Unraveling the Financial Story of QuidelOrtho</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: QuidelOrtho's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.27%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: QuidelOrtho's net margin excels beyond industry benchmarks, reaching -2.74%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): QuidelOrtho's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.63% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): QuidelOrtho's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.29%, the company showcases efficient use of assets and strong financial health.
Debt Management: QuidelOrtho's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.86.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

QDEL

Where QuidelOrtho Stands With Analysts

WIIM

QuidelOrtho shares are trading higher after the company reported better-than-expected Q4 financial results. Also, UBS maintained a Neutral rating ont he stock and raised its price target from $43 to $45.

RBC Capital analyst Conor McNamara maintains QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) with a Outperform and lowers the price target from $64 to $61.

News

Price Target

RBC Capital Maintains Outperform on QuidelOrtho, Lowers Price Target to $61

UBS analyst John Sourbeer maintains QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) with a Neutral and raises the price target from $43 to $45.

UBS Maintains Neutral on QuidelOrtho, Raises Price Target to $45

QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) is looking for FY2025 Adj EPS of $2.07-$2.57 vs $2.44 analyst estimate. sees sales of $2.600 billion-$2.810 billion vs $2.76 billion analyst estimate.

Guidance

QuidelOrtho Sees FY2025 Adj EPS $2.07-$2.57 vs $2.44 Est; Sees Sales $2.600B-$2.810B vs $2.76B Est

QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.59 by 6.78 percent. This is a 46.15 percent decrease over earnings of $1.17 per share from the same period last year. The company reported quarterly sales of $707.80 million which beat the analyst consensus estimate of $699.16 million by 1.24 percent. This is a 4.69 percent decrease over sales of $742.60 million the same period last year.

Earnings

Earnings Beats

QuidelOrtho Q4 2024 Adj EPS $0.63 Beats $0.59 Estimate, Sales $707.80M Beat $699.16M Estimate

ACRE

AEIS

AEMD

ALCO

ALKS

AMWL

ASND

ASPN

ATRC

AVXL

AYTU

BIIB

BROS

BXMT

CAMT

CGNX

CHEF

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

EQIX

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HOOD

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PAYC

PEGA

PLMR

PODC

PXLW

PYPD

QMCO

QTWO

Earnings Scheduled For February 12, 2025

<h3>Gainers</h3>
<ul>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) shares increased by 134.7% to $4.46 during Tuesday's pre-market session. The company's market cap stands at $37.9 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares increased by 65.04% to $0.51. The market value of their outstanding shares is at $26.2 million. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) shares moved upwards by 30.29% to $0.28. The company's market cap stands at $45.6 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock increased by 18.72% to $2.98. The company's market cap stands at $39.6 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock rose 17.56% to $5.02. The market value of their outstanding shares is at $5.6 million. </li>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) stock moved upwards by 15.94% to $0.83. The market value of their outstanding shares is at $189.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock decreased by 41.8% to $3.84 during Tuesday's pre-market session. The company's market cap stands at $6.6 million. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares declined by 25.89% to $1.46. The company's market cap stands at $5.8 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares decreased by 23.23% to $0.62. The company's market cap stands at $1.9 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares decreased by 17.99% to $3.01. The company's market cap stands at $4.3 million. </li>
<li>QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) stock decreased by 16.5% to $37.25. The company's market cap stands at $2.5 billion. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares decreased by 15.5% to $1.8. The market value of their outstanding shares is at $23.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIFF

ATPC

AVGR

ERNA

KAPA

PHIO

PIII

PRTG

SLRX

VXRT

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

QuidelOrtho Sees Prelim Q4 Revenue $702M-$707M Vs $698.041M Est.

QuidelOrtho shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $44 to $50.

Citigroup analyst Patrick Donnelly upgrades QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) from Neutral to Buy and raises the price target from $44 to $50.

Upgrades

Citigroup Upgrades QuidelOrtho to Buy, Raises Price Target to $50

Jefferies analyst Tycho Peterson initiates coverage on QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) with a Hold rating and announces Price Target of $43.

Initiation

Jefferies Initiates Coverage On QuidelOrtho with Hold Rating, Announces Price Target of $43

On Tuesday, QuidelOrtho Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>)&nbsp;priced the previously announced underwritten secondary offering by Carlyle Partners VI Cayman Holdings of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42079373/quidelortho-corporation-announces-pricing-of-secondary-offering-of-common-stock-by-the-carlyle-gro" rel="noreferrer noopener">8.26 million shares</a>.
The selling stockholder will receive all of the proceeds. The company is not <a href="https://www.benzinga.com/pressreleases/24/11/b42076127/quidelortho-corporation-announces-secondary-offering-of-common-stock-by-the-carlyle-group" target="_blank" rel="noreferrer noopener">selling any shares</a>.
The last reported sale price of QuidelOrtho&#8217;s common stock on Nov. 19 was $38.58 per share. Goldman Sachs &amp; Co. LLC is acting as the sole underwriter.
William Blair analysts noted that Carlyle sold some of its shares earlier this summer through smaller transactions. At that time, investors had suggested block trades or secondary transactions for any further sales by Carlyle. Tuesday&#8217;s announcement aligns with these preferences, which investors may view positively.
While some might interpret this move as a lack of confidence in QuidelOrtho's ongoing improvements, the analysts do not share that view.
Instead, they emphasize considering factors like Carlyle's long ownership period, as the firm originally acquired Ortho Clinical in 2014.
William Blair analysts write, &#8220;We take this as a long-term net-positive for the stock as it removes one of the overhangs that came up in investor conversations around the name.&#8221;
William Blair reiterates a Market Perform rating.
Price Action: QDEL stock is down 4.2% at $36.96 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42092417/salesforce-launches-tools-to-simplify-ai-agent-testing-and-deployment" target="_blank" rel="noreferrer noopener">Salesforce Tool Aims To Simplify AI Agent Testing, Deployment</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Health Care

Trading Ideas

General

Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Shares of Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) fell sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/POWL/earnings">reported worse-than-expected fourth-quarter revenue results.</a>
Powell Industries reported quarterly earnings of $3.77 per share which beat the analyst consensus estimate of $3.55 per share. The company reported quarterly sales of $275.06 million which missed the analyst consensus estimate of $286.49 million.
Powell Industries shares dipped 15.4% to $264.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) shares declined 16.3% to $129.62 in pre-market trading following downbeat quarterly results.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) shares dipped 13.4% to $39.18 in pre-market trading after jumping 24% on Tuesday.</li>
<li>Silvercorp Metals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVM#NYSE">SVM</a>) fell 11.3% to $3.59 in pre-market trading after the company announced a $130 million convertible senior notes offering.</li>
<li>QuidelOrtho Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) fell 6.7% to $36.01 in today's pre-market trading after the company announced the pricing of secondary offering of common stock by the Carlyle Group.</li>
<li>The First of Long Island Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLIC#NASDAQ">FLIC</a>) fell 5.4% to $13.13 in pre-market trading.</li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) fell 4.8% to $236.90 in pre-market trading.</li>
<li>XP Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) fell 4.1% to $16.00 in pre-market trading following weak quarterly earnings.</li>
<li>Dianthus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) fell 2.3% to $21.77 in pre-market trading after declining more than 5% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42069785/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

DNTH

DXYZ

FLIC

POWL

Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Shares of Keysight Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) rose sharply in today's pre-market trading reported <a href="https://www.benzinga.com/news/earnings/24/11/42075636/keysight-technologies-stock-jumps-on-q4-earnings-revenue-beat-eps-beat-confidence-in-our-ability-to-outperform">better-than-expected earnings for its fourth quarter.</a>
Keysight reported quarterly earnings of $1.65 per share which beat the analyst consensus estimate of $1.57. The company reported quarterly sales of $1.287 billion which beat the analyst consensus estimate of $1.258 billion.
The company said it sees first-quarter revenue of $1.265 billion to $1.285 billion and adjusted earnings of $1.65 to $1.71 per share.
Keysight shares jumped 9.3% to $166.20 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) gained 63.6% to $0.2663 in pre-market trading after jumping 22% on Tuesday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) rose 59.3% to $1.45 in pre-market trading after the company entered into strategic collaboration with SeaTrepid to integrate and test its ToolKITT software on remotely operated vehicles.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) gained 41.2% to $1.92 in pre-market trading following third-quarter results.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) gained 30.7% to $0.1524 in pre-market trading after jumping around 18% on Tuesday.</li>
<li>JX Luxventure Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXJT#NASDAQ">JXJT</a>) gained 26.2% to $1.64 in pre-market trading after declining around 12% on Tuesday.</li>
<li>KORE Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) gained 25.1% to $2.29 in pre-market trading after the company reported better-than-expected quarterly sales results.</li>
<li>Algorhythm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) gained 23.4% to $0.3150 in pre-market trading after reporting third-quarter results.</li>
<li>Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) climbed 22.2% to $0.9993 in pre-market trading after the company was granted U.S. Patent No. 12,144,815 titled &#8220;Use of Aprepitant for Treating Alzheimer&#8217;s Disease.&#8221;</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 20.8% to $5.55 in pre-market trading. Kingsoft Cloud, on Tuesday, reported a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), up by 16.0% year-on-year, beating the analyst consensus estimate of $247.46 million.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares tumbled 26.4% to $1.03 in pre-market trading after jumping 162% on Tuesday. The company announced a 1-for-4 reverse stock split.</li>
<li>X3 Holdings Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) fell 27.4% to $0.1050 in pre-market trading. XTKG announced a 1-for-20 share consolidation.</li>
<li>Solidion Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares fell 21.2% to $0.5003 in pre-market trading following third-quarter results.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) declined 16.7% to $0.3912 in pre-market trading after jumping 123% on Tuesday. Volato Group, on Monday, reported a year-over-year increase in third-quarter financial results.</li>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares fell 16.6% to $0.9180 in pre-market trading after dipping 11% on Tuesday. The company announced a $6.9 million direct offering and private placement.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) dipped 15.4% to $264.00 in pre-market trading after the company reported worse-than-expected fourth-quarter revenue results.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) shares dipped 13.4% to $39.18 in pre-market trading after jumping 24% on Tuesday.</li>
<li>Workhorse Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) fell 13.1% to $1.06 in pre-market trading after posting quarterly results.</li>
<li>Silvercorp Metals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVM#NYSE">SVM</a>) fell 11.3% to $3.59 in pre-market trading after the company announced a $130 million convertible senior notes offering.</li>
<li>QuidelOrtho Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) fell 6.7% to $36.01 in today's pre-market trading after the company announced the pricing of secondary offering of common stock by the Carlyle Group.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42069785/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>

DBGI

HCWB

HOTH

JXJT

KEYS

KITT

KORE

PRFX

RIME

SOAR

TNXP

TVGN

WKHS

XTKG

Why Keysight Technologies Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Reported Earlier, QuidelOrtho Prices Secondary Offering Of 8.26M Shares By Carlyle Group

Offerings

QuidelOrtho Corporation Announces Secondary Offering Of  8,260,183 Shares By Carlyle Group

As of Nov. 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Airsculpt Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>)</h3>
<ul>
<li>On Nov. 8, AirSculpt Technologies posted better-than-expected quarterly results. &#8220;Our revenue and Adjusted EBITDA for the quarter were in line with our expectations with the period including progress on our strategy despite continued challenges in the consumer environment,&#8221; said Dennis Dean, Interim Chief Executive Officer and Chief Financial Officer of AirSculpt Technologies, Inc. The company's stock gained around 42% over the past five days and has a <a href="https://www.benzinga.com/quote/AIRS">52-week high of $8.88</a>.</li>
<li>RSI Value: 81.89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>AIRS Price Action: Shares of Airsculpt Technologies gained 20.7% to close at $8.68 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Quidelortho Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>)</h3>
<ul>
<li>On Nov. 7, QuidelOrtho reported better-than-expected third-quarter financial results and issued FY24 revenue above estimates. &#8220;We delivered solid third quarter results, giving us confidence that our strategic priorities and focus on our customers, business growth and margin improvement are gaining traction,&#8221; said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. The company's stock gained around 11% over the past five days and <a href="https://www.benzinga.com/quote/QDEL">has a 52-week high</a> of $75.86.</li>
<li>RSI Value: 74.63</li>
<li>QDEL Price Action: Shares of Quidelortho gained 12.6% to close at $43.75 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Nuvation Bio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>)</h3>
<ul>
<li>On Nov. 6, Nuvation Bio reported financial results for the third quarter ended Sept, 30, and provided a business update. David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio stated: &#8220;In the third quarter, we continued to execute on our goal of bringing taletrectinib to people living with ROS1-positive NSCLC as quickly as possible, which has been our focus since we closed the acquisition of AnHeart Therapeutics earlier this year. In October, we completed the rolling submission of our NDA for line agnostic full approval of taletrectinib in advanced ROS1-positive NSCLC, which was supported by the pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies that we presented at ESMO. We believe that these data – a confirmed objective response rate of 89% and median duration of response approaching four years in the TKI-naïve setting – are the strongest data seen to date in the ROS1 space and increase taletrectinib&#8217;s potential to become a best-in-class treatment option.&#8221; The company's stock gained around 25% over the past five days and has a <a href="https://www.benzinga.com/quote/NUVB">52-week high</a> of $4.16.</li>
<li>RSI Value: 71.61</li>
<li>NUVB Price Action: Shares of Nuvation Bio gained 9.9% to close at $2.88 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Insulet Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>)</h3>
<ul>
<li>On Nov. 7, Insulet reported better-than-expected third-quarter financial results. &#8220;We continue to achieve significant milestones and robust revenue growth,&#8221; said Jim Hollingshead, President and Chief Executive Officer. The company's stock jumped around 14% over the past five days and has a 52-week high is $275.52.</li>
<li>RSI Value: 87.19</li>
<li>PODD Price Action: Shares of Insulet gained 9.4% to close at $268.00 on Friday. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41871463/dow-sp-500-notch-best-week-of-year-as-tesla-surges-post-trump-win-investor-sentiment-improves-fear-greed-index-remains-in-neutral-zone">Dow, S&amp;P 500 Notch Best Week Of Year As Tesla Surges Post Trump Win: Investor Sentiment Improves, Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Short Ideas

AIRS

NUVB

PODD

Top 4 Health Care Stocks That May Plunge This Quarter

Management

QuidelOrtho Determined To Terminate Employment Of Michael S. Iskra, Co's Executive VP And Chief Commercial Officer And Robert J. Bujarski, Co's EVP And Chief Operating Officer

QuidelOrtho shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue above estimates.

Press Releases

QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group

QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group

QuidelOrtho Announces Appointment of Two Independent Directors to its Board

QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates

QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024

QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results

QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference

Comments

QuidelOrtho

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO